253 related articles for article (PubMed ID: 24385540)
1. MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma.
Ito M; Teshima K; Ikeda S; Kitadate A; Watanabe A; Nara M; Yamashita J; Ohshima K; Sawada K; Tagawa H
Blood; 2014 Mar; 123(10):1499-511. PubMed ID: 24385540
[TBL] [Abstract][Full Text] [Related]
2. Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.
Ikeda S; Kitadate A; Ito M; Abe F; Nara M; Watanabe A; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2016 Mar; 7(12):13563-74. PubMed ID: 26789110
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
4. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.
Matsuda Y; Ikeda S; Abe F; Takahashi Y; Kitadate A; Takahashi N; Wakui H; Tagawa H
Cancer Sci; 2022 Apr; 113(4):1208-1219. PubMed ID: 35133054
[TBL] [Abstract][Full Text] [Related]
6. CCL20/CCR6 promotes cell proliferation and metastasis in laryngeal cancer by activating p38 pathway.
Lu E; Su J; Zhou Y; Zhang C; Wang Y
Biomed Pharmacother; 2017 Jan; 85():486-492. PubMed ID: 27916417
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
8. The (miR)e of CTCL.
Mishra A; Garzon R
Blood; 2014 Mar; 123(10):1438. PubMed ID: 24627548
[TBL] [Abstract][Full Text] [Related]
9. DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway.
Guo W; Li H; Liu H; Ma X; Yang S; Wang Z
Oncol Rep; 2019 Sep; 42(3):1075-1089. PubMed ID: 31322256
[TBL] [Abstract][Full Text] [Related]
10. The effects of the CCR6/CCL20 biological axis on the invasion and metastasis of hepatocellular carcinoma.
Du D; Liu Y; Qian H; Zhang B; Tang X; Zhang T; Liu W
Int J Mol Sci; 2014 Apr; 15(4):6441-52. PubMed ID: 24743888
[TBL] [Abstract][Full Text] [Related]
11. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
[TBL] [Abstract][Full Text] [Related]
12. CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production.
Zeng W; Chang H; Ma M; Li Y
Exp Mol Pathol; 2014 Aug; 97(1):184-90. PubMed ID: 24984269
[TBL] [Abstract][Full Text] [Related]
13. CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer.
Benkheil M; Van Haele M; Roskams T; Laporte M; Noppen S; Abbasi K; Delang L; Neyts J; Liekens S
Exp Cell Res; 2018 Nov; 372(2):168-177. PubMed ID: 30287142
[TBL] [Abstract][Full Text] [Related]
14. Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer.
Ghadjar P; Loddenkemper C; Coupland SE; Stroux A; Noutsias M; Thiel E; Christoph F; Miller K; Scheibenbogen C; Keilholz U
J Cancer Res Clin Oncol; 2008 Nov; 134(11):1181-9. PubMed ID: 18465142
[TBL] [Abstract][Full Text] [Related]
15. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
Kohnken R; Wen J; Mundy-Bosse B; McConnell K; Keiter A; Grinshpun L; Hartlage A; Yano M; McNeil B; Chakravarti N; William B; Bradner JE; Caligiuri MA; Porcu P; Mishra A
Blood; 2018 Feb; 131(7):771-781. PubMed ID: 29180399
[TBL] [Abstract][Full Text] [Related]
16. TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer.
Coperchini F; Pignatti P; Carbone A; Bongianino R; Di Buduo CA; Leporati P; Croce L; Magri F; Balduini A; Chiovato L; Rotondi M
Tumour Biol; 2016 Apr; 37(4):5569-75. PubMed ID: 26577851
[TBL] [Abstract][Full Text] [Related]
17. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.
Hirota K; Yoshitomi H; Hashimoto M; Maeda S; Teradaira S; Sugimoto N; Yamaguchi T; Nomura T; Ito H; Nakamura T; Sakaguchi N; Sakaguchi S
J Exp Med; 2007 Nov; 204(12):2803-12. PubMed ID: 18025126
[TBL] [Abstract][Full Text] [Related]
18. Panel of miR-150 and linc00673, regulators of CCR6/CCL20 may serve as non-invasive diagnostic marker of non-small cell lung cancer.
Baran K; Kordiak J; Jabłoński S; Brzeziańska-Lasota E
Sci Rep; 2023 Jun; 13(1):9642. PubMed ID: 37316552
[TBL] [Abstract][Full Text] [Related]
19. CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis.
Nandi B; Pai C; Huang Q; Prabhala RH; Munshi NC; Gold JS
PLoS One; 2014; 9(5):e97566. PubMed ID: 24866282
[TBL] [Abstract][Full Text] [Related]
20. CCL20/CCR6 expression profile in pancreatic cancer.
Rubie C; Frick VO; Ghadjar P; Wagner M; Grimm H; Vicinus B; Justinger C; Graeber S; Schilling MK
J Transl Med; 2010 May; 8():45. PubMed ID: 20459729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
